The curative and palliative potential of the monoclonal antibody MOv18 labelled with 211At in nude mice with intraperitoneally growing ovarian cancer xenografts: A long-term study

Acta Oncologica

Volumn 39, Issue 6, 2000, Pages 741-745

  Andersson, H ^a   Lindegren, S ^a   Back T ^a   Jacobsson, L ^a   Leser, G ^a   Horvath, G ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ASTATINE 211; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MOV 18; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ASCITES; CANCER GROWTH; CANCER SURVIVAL; CONFERENCE PAPER; DRUG EFFICACY; FEMALE; ISOTOPE LABELING; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SURVIVAL TIME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ASCITES; ASTATINE; FEMALE; HUMANS; IMMUNOCONJUGATES; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PALLIATIVE CARE; PERITONEAL NEOPLASMS; RADIOISOTOPES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033679354     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418600750063820     Document Type: Conference Paper

References (29)

1. Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy
2. Intraperitoneal therapy of ovarian cancer
3. Is there a role for consolidation or salvage radiotherapy after chemotherapy in advanced epithelial ovarian cancer?
4. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody
5. Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: Clinical results in patients with minimal residual disease of ovarian cancer
6. Radioimmunotherapy with alphaparticle emitting radioimmunoconjugates
7. 211At-labelled monoclonal anti-body MOv18
8. Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity
9. Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3
10. 131I radiotherapy
11. Comparative immunohistochemical study of four monoclonal antibodies directed against ovarian carcinoma-associated antigens
12. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity
13. Folate-binding protein is a marker for ovarian cancer
14. Chloramine-T in high-specific-activity radioiodination of antibodies using N-succinimidyl-3-(trimethylstannyl)benzoate as an intermediate
15. 125I according to the m-MeATE method or the Iodogen method in nude mice with ovarian cancer xenografts
16. Evaluation of the immunoreactive fraction of an anti-tumour monoclonal antibody
17. Membrane association and shedding of the GPI-anchored Ca-MOv18 antigen in human ovary carcinoma cells
18. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess
19. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice
20. 211At in a murine intraperitoneal tumor model
21. 90Y
22. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1
23. Radioimmunotherapy of ovarian cancer with radiolabelled monoclonal antibodies: Biological basis, present status and future perspectives
24. Antibody-guided irradiation of malignant ascites in ovarian cancer: A new therapeutic method possessing specifiicity against cancer cells
25. Resolution of malignant ascites after intraperitoneal chemotherapy in women with carcinoma of the ovary
26. Summary of ten years of the use of radioactive colloids in intracavtary therapy
27. Effecy of intraperitoneal recombinat human tumour necrosis factor alpha on malignant ascites
28. Intraperitoneal recombinant interferon-alpha 2b for recurrrent malignant ascites due to ovarian cancer
29. 211At]astato-3-pyridinecarboxylate